Postgraduate course in Breast Cancer

CERTIFICATION

Diploma/Postgraduate course in Breast Pathology Senology issued as UB-specific diploma/postgraduate course.

DURATION

Nov 2020 – Jun 30 2021
Academic calendar

LANGUAGE

Spanish
Some lessons may be in English

OBJECTIVE TARGET

Gynaecologists, surgeons, pathologists, radiologists and oncologists.

ENROLLMENT PERIOD

From Sep 7 2020 to Oct 3 2020

Format

Online

MANAGEMENT

Director: Aleix Prat Aparicio
Co-directors: Miquel Prats de Puig and Edelmiro Iglesias Martínez

COST

2,850€ (Increase of 10% to the amount, up to a maximum of 70€, in terms of administrative fees).

ACCESS REQUIREMENTS

Degree in Medicine or Nursing

CREDITS

30 ECTS

NUMBER OF PLACES

Limited

Diploma/postgraduate course in Breast Cancer is a UB-specific degree from the Medicine Faculty and it consists of a single course.

The postgraduate course is intended to give a theorical training in breast pathology, from a knowledge about its molecular biology, development and use of biomarkers and clinic research, to the diagnosis and treatment of localized and advanced breast cancer. In order to complete thus training with the practical part, it is offered the possibility to extend another course and obtain a Master’s degree.

Even accepting that it is possible to know totally or partially the program and that some lessons may be of greater or lesser interest depending on the specialty, attendance and participation in all the master’s activities will be required, and passing evaluations, without contemplating the validation of other studies, knowledge accreditation, welfare efforts, etc.

The post-grade course is composed of one academic course, which form a total of 30 academic credits ECTS (1ECTS = 25 class hours).

1 year
MODULE I: Molecular Biology (10 ECTS)
MODULE II: Early breast cancer (10 ECTS)
MODULE III: Metastatic breast cancer (10 ECTS)

Alexis Rodríguez Gallego

Médico especialista en Farmacología Clínica

Clinical Pharmacology specialist. He has a master’s degree in Bioethics and Law and is a member of the CEIm (Comité de Ética de Investigación con medicamentos) of the Hospital Vall d’Hebrón in Barcelona.

Atanasio Pandiella

Professor of Research at the Centro de Investigación del Cáncer of Salamanca.

His training includes research at the CNR, Ospedale San Raffaele in Milán and the Memorial Sloan Kettering Cancer Center in New York. His research focuses on the functional characterization of molecules involved in different human solid tumors, in particular breast tumors.

Ana Janic

Group Leader at Universidad Pompeu Fabra

Graduated from the University of Belgrade and PhD in Biomedicine from IRB-Barcelona. She is currently Professor Tenure-Track at the Universidad Pompeu Fabra of Barcelona, where she studies how tumor suppressors protect us from the development of cancer.

Oriol Casanovas

Group Leader at IBIDELL

Researcher of recognized international prestige with extensive knowledge and experience in basic and translational research of murine models of cancer and tumor angiogenesis. His scientific studies have been published in highly regarded journals in the cancer field.

Aranzazu Fernández

Medical Oncologist

Post-doctoral research associate in the laboratory run by Charles M.Perou at the UNC Lineberg Comprehensive Cancer Center. Her research interest is focused on Breast Cancer Genomic Biomarkers.

Violeta Serra

Group Leader of the VHIO Experimental Therapies Group

PhD from the University of Newcastle and postdoctoral stays in Charité, Berulon and CNIO. She is currently the principal investigator of the VHIO Experimental Therapies Group, where she studies the identification of biomarkers response to targeted therapies in breast cancer.

José Rios

Coordinator of the Medical Statistics Platform of IDIBAPS-Hospital Clínic of Barcelona.

More than 25 years of experience in statistical-methodological support with more than 200 indexed papers. He currently coordinates the medical statistical platform of IDIBAPS-Hospital Clínic and is an associate professor at the Faculty of Medicine of the UAB. He also collaborates with independent research groups like SOLTI.

Dolors Soy Muner

Head of Pharmacy at Hospital Clínic

PhD in Pharmacy from the Universidad de Barcelona and specialist in Hospital Pharmacy. She is an associate professor at the Faculty of Pharmacy of the Universidad de Barcelona while continuing her research. Her main lines of research focus on knowledge of the dose-concentration-effect relationships of drugs.

Orland Diez

Senior Researcher of the Hereditary Cancer Group of VHIO

PhD in Biology, physician at the Clinical and Molecular Genetics Area of the Hospital Universitario Vall d’Hebron and Senior Researcher of the Hereditary Cancer Group of the Vall d’Hebron Instituto Oncológico (VHIO).

Manel Esteller

Director of the Instituto de Investigación contra la Leucemia Josep Carreras

PhD of Medicine and Surgery from the Universidad de Barcelona. He is currently Director of the Instituto de Investigación contra la Leucemia Josep Carreras (IJC), research professor at ICREA and Tenured Full Professor of genetics at the School of Medicine of the Universidad de Barcelona. Author of more than 500 scientific publications and awarded among others with the Severo Ochoa Award and the Genetics and Oncology National Awards. His research focuses on the epigenetic mechanisms responsible for human disease, mainly cancer.

Patricia Villagrasa

Scientific Director of the Grupo Académico de Investigación Clínica y Traslacional en Cáncer SOLTI.

PhD in Molecular Biology and Biochemistry from the Universidad Autónoma de Barcelona. After more than 10 years in cancer research, she joined SOLTI in 2013 after a postdoctoral period at Columbia University (New York, USA) focused on breast cancer. Currently, she is the Scientific Director of the Grupo Académico de Investigación Clínica y Traslacional en Cáncer SOLTI, where she coordinates all operations and the scientific team, which supports the design and management of clinical trials for all researchers in the group.

Oscar Salamanca

Managing Director of APICES

Pharmacist and MBA from the Instituto de Empresa. With more than 25 years of experience in the drug research and development sector and with extensive management experience in the field of clinical research in CROs (Contract Research Organizations) and in the Oncology area. He is currently Managing Director of APICES (European CRO).

Judith Balmaña

Group Leader of the Hereditary Cancer Genetics Group in the Medical Oncology Service at VHIO

She specialized as a medical oncologist and is currently Head of the Hereditary Cancer Genetics Group in the Medical Oncology Service at the Hospital Universitario Vall d’Hebron and at the Vall d’Hebron Insitut d’Oncologia (VHIO). Her research areas cover the genetic epidemiology of hereditary breast and ovarian cancer, the clinical and psychological impact of genetic testing, and the clinical development of targeted therapies for patients with hereditary breast cancer.

Claudia Arnedo

PhD student at the Biomedical Genomics laboratory (IRB)

Graduated in Biomedical Sciences from the Universidad de Barcelona. In 2018, she obtained a Master's degree in Bioinformatics for Health Sciences from the Universidad Pompeu Fabra. She is currently carrying out her doctoral thesis in the Biomedical Genomics laboratory (IRB), led by Dr. Núria López Bigas, studying cancer driver mutations.

Toni Hurtado

Researcher at the Biosciences Department, Faculty of Medicine (University of Barcelona)

PhD at the Vall d’Hebron Institut de Recerca In late 2011, he became a group leader at the Norwegian Center for Molecular Medicine. He recently joined the Department of Biosciences at the Faculty of Medicine (Universidad de Barcelona), where he has focused on investigating the mechanisms related to the response to anti-ER drugs in breast tumors growth.

Isaac García-Murillas

El Dr. Isaac García-Murillas es un científico del personal del Centro de Investigación de Cáncer de Mama

Instituto de Investigación del Cáncer en Londres, donde se enfoca en la utilidad clínica del ADNc como biomarcador para cuantificar la enfermedad residual mínima, monitorear la respuesta al tratamiento e identificar la emergencia. de resistencia a los medicamentos.

Aleix Prat Aparicio

Master in Breast Pathology and Breast Cancer co-director

Bachelor of Medicine from the University of Barcelona PhD from the Universidad Autónoma de Barcelona. Master in Molecular Oncology at the Centro Nacional de Investigaciones Oncológicas (CNIO). PostDoctoral fellowship at the University of North Carolina, USA.

Dr. Miguel Prats de Puig

Master in Breast Pathology and Breast Cancer co-director

Renowned gynecologist specialist with extensive experience in senology- breast pathology. He has completed training stays in highly prestigious breast pathology units, both nationally and internationally. He has extensive surgical training in benign and malignant processes of the breast, including techniques as selective biopsy of the sentinel lymph node and intraoperative breast ultrasound. He is a pioneer and a reference in Spain in breast surgery with intraoperative radiation therapy. In addition to clinical practice, he also teaches at different universities and is the author of various chapters in books on breast pathology. Furthermore, he is a member of the main medical societies of his specialty at an international level.

Master in Breast Pathology and Breast Cancer co-director.

MORE INFORMATION ADMISSION